Last updated on November 2019

A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies

Find a site near you

Start Over

Pediatric Neurology PA

Orlando, FL United States
  Connect »

Rare Disease Research, LLC

Atlanta, GA United States
  Connect »

Mayo Clinic - PPDS

Rochester, MN United States
  Connect »

Wake Forest Baptist Medical Center

Winston-Salem, NC United States
  Connect »

Austin Hospital

Heidelberg West, Australia
  Connect »

Phoenix Children's Hospital

Phoenix, AZ United States
  Connect »

Children's Hospital Los Angeles

Los Angeles, CA United States
  Connect »

Cook Children's Medical Center

Fort Worth, TX United States
  Connect »